The Middle East prefilled syringes market size was estimated at USD 135.9 Million in 2025 and is projected to reach USD 253.4 million by 2033, growing at a CAGR of 8.10% from 2025 to 2033. The increase in chronic diseases in the Middle East region, such as cancer, and a growing focus on early disease diagnosis and chronic disease management, continue to increase demand for safer and more efficient drug delivery systems like prefilled syringes.
Furthermore, government initiatives to widen reimbursement coverage and access to healthcare have increased the prospects for mindful use of prefilled syringes in hospitals and across various sectors, especially in Gulf countries, which have successfully improved their healthcare infrastructure.
The Middle East has witnessed a notable increase in product entries and strategic expansions by leading pharmaceutical companies in recent months. For instance, in May 2025, Pfizer launched the region’s first prefilled autoinjector therapy for hemophilia in the UAE, providing patients with a once-weekly, self-administered treatment that reduces hospital visits and improves convenience. This initiative aims to enhance access to advanced injectable therapies, but the key takeaway is the increasing use of patient-friendly drug delivery systems in the region.
The medical device markets in the region are the largest in the United Arab Emirates and Saudi Arabia. Ongoing disease burden, rising healthcare expenditures, and greater privatization in healthcare are some of the major drivers expected to boost the prefilled syringe industry throughout this forecast period.
The prevalence of chronic diseases in the Middle East is significant, primarily diabetes, and this increases the demand for prefilled syringes. Moreover, patients with diabetes often rely on prefilled syringes due to the convenience and easy usage associated with these products. One of the key benefits of these syringes is their enhanced dose accuracy, along with the decreased risk of contamination. As chronic disease continues to grow in this region, prefilled syringes will likely be more frequently adopted by both patients and healthcare providers, thus fueling market growth.
Along with this rising demand, the manufacturing companies in the Middle East are expanding local production and distribution of prefilled syringes. For instance, Al Shifa Medical Syringe Manufacturing Co. in Saudi Arabia produces prefilled syringes with sterile saline solutions, Julphar in the UAE offers a range of prefilled injectable therapies, and Fresenius Kabi provides its Simplist prefilled syringes across the region. These initiatives highlight the strategic efforts of manufacturers to meet growing healthcare needs and improve access to advanced drug delivery systems in the Middle East.
This product will be delivered within 1-3 business days.
Furthermore, government initiatives to widen reimbursement coverage and access to healthcare have increased the prospects for mindful use of prefilled syringes in hospitals and across various sectors, especially in Gulf countries, which have successfully improved their healthcare infrastructure.
The Middle East has witnessed a notable increase in product entries and strategic expansions by leading pharmaceutical companies in recent months. For instance, in May 2025, Pfizer launched the region’s first prefilled autoinjector therapy for hemophilia in the UAE, providing patients with a once-weekly, self-administered treatment that reduces hospital visits and improves convenience. This initiative aims to enhance access to advanced injectable therapies, but the key takeaway is the increasing use of patient-friendly drug delivery systems in the region.
The medical device markets in the region are the largest in the United Arab Emirates and Saudi Arabia. Ongoing disease burden, rising healthcare expenditures, and greater privatization in healthcare are some of the major drivers expected to boost the prefilled syringe industry throughout this forecast period.
The prevalence of chronic diseases in the Middle East is significant, primarily diabetes, and this increases the demand for prefilled syringes. Moreover, patients with diabetes often rely on prefilled syringes due to the convenience and easy usage associated with these products. One of the key benefits of these syringes is their enhanced dose accuracy, along with the decreased risk of contamination. As chronic disease continues to grow in this region, prefilled syringes will likely be more frequently adopted by both patients and healthcare providers, thus fueling market growth.
Along with this rising demand, the manufacturing companies in the Middle East are expanding local production and distribution of prefilled syringes. For instance, Al Shifa Medical Syringe Manufacturing Co. in Saudi Arabia produces prefilled syringes with sterile saline solutions, Julphar in the UAE offers a range of prefilled injectable therapies, and Fresenius Kabi provides its Simplist prefilled syringes across the region. These initiatives highlight the strategic efforts of manufacturers to meet growing healthcare needs and improve access to advanced drug delivery systems in the Middle East.
Middle East Prefilled Syringes Market Report Segmentation
This report forecasts revenue growth at country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, the analyst has segmented the Middle East prefilled syringes market report based on product and application.Type Outlook (Revenue, USD Million, 2021-2033)
- Disposable
- Reusable
Material Outlook (Revenue, USD Million, 2021-2033)
- Glass
- Plastic
Application Outlook (Revenue, USD Million, 2021-2033)
- Vaccines and Immunizations
- Anaphylaxis
- Rhumatoid Arthritis
- Diabetes
- Autoimmune Diseases
- Onchology
- Others
Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Mail order Pharmacies
- Ambulatory Surgery Centers
Region Outlook (Revenue, USD Million, 2021-2033)
- Middle East
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segmental and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Middle East Prefilled Syringes Market Variables, Trends & Scope
Chapter 4. Middle East Prefilled Syringes Market: Type Estimates & Trend Analysis
Chapter 5. Middle East Prefilled Syringes: Material Estimates & Trend Analysis
Chapter 6. Middle East Prefilled Syringes: Application Estimates & Trend Analysis
Chapter 7. Middle East Prefilled Syringes: Channel Estimates & Trend Analysis
Chapter 8. Middle East Prefilled Syringes Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Middle East Prefilled Syringes market report include:- BD
- Gerresheimer AG
- SCHOTT Pharma AG
- Stevanato Group
- Nipro Corporation
- Terumo
- West Pharmaceuticals
- Fresenius
- Catalent
- Aptar Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | September 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 135.9 Million |
| Forecasted Market Value ( USD | $ 253.4 Million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
